Clinical trial NCT03363893: Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies
Official title: A Modular, Multipart, Multiarm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of CT7001 Alone and in Combination With Anti-cancer Treatments in Patients With Advanced Malignancies
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Advanced Solid Malignancies
Keywords: Neoplasms
Lead sponsor: Carrick Therapeutics Limited
Sponsor class: INDUSTRY
First posted: 2017-12-06
Enrollment: 124
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Modular design
Primary purpose: TREATMENT

Brief summary: This is a modular, Phase I/II, multicentre study to investigate CT7001 monotherapy in advanced solid malignancies and to further investigate CT7001 as monotherapy or in combination with standard therapy in specific participant groups with Triple Negative Breast Cancer (TNBC), Castrate Resistant Prostate Cancer (CRPC) and in combination with fulvestrant for patients with hormone receptor-positive (HR+ve) / human epidermal growth factor-2 negative (HER2-ve) breast cancer.

Detailed description: Module 1 comprises two sequential parts:

* Part A: First-in-human (FiH) dose escalation investigating the safety and tolerability of CT7001 to identify the minimum biologically active dose (MBAD) and maximum tolerated dose (MTD). Part A also includes a cohort expansion for breast cancer participants only: this includes sequential tumour biopsies for evaluation of pharmacokinetic (PK), pharmacodynamic (PD) and tumour responses. The module is completed.
* Part B: To refine the safety, tolerability, and PK and PD profiles of CT7001 monotherapy in participants with advanced solid malignancies from up to four tumour- specific cohorts, which may include, but is not limited to, triple-negative breast cancer, ovarian cancer, small-cell lung cancer and prostate cancer.

  * Part B, Cohort 1, Triple-Negative Breast Cancer (M1B-1 TNBC) treated with CT7001 as monotherapy. The module is completed.
  * Part B, Cohort 2, Prostate Cancer (M1B-2 CRPC) treated with CT7001 as monotherapy. The module is completed.
* Module 4 is a study investigating the effect of food on the PK of CT7001 monotherapy in participants with advanced solid malignancies. The module is completed.
* Module 2 is a Phase Ib/II, 3-part safety and efficacy study in participants with hormone-receptor positive (HR+ve) and human epidermal growth factor-2 negative (HER2-ve) breast cancer. This module will dose CT7001 in combination with fulvestrant. Module 2 consists of 3 parts - Part A, Part B and Part C. Module 2 Part A recruitment is completed. Part B is double-blind, randomized and placebo-controlled Part C will be a crossover from Part B. Module 2B/C were planned to be open in 2022 but the modules will not be progressed further.
* Module 6 is a Phase 1 study to explore the tolerability of, and the total and peak exposure of, an enteric capsule formulation of CT7001 \[CT7001(EC)\], when given as monotherapy to patients with advanced solid malignancies. Module 6 will not be initiated.

Eligibility criteria: Core Inclusion Criteria:

1. ECOG performance status 0 or 1 with no deterioration over the previous 2 weeks
2. Estimated life expectancy of greater than 12 weeks
3. Ability to swallow and retain oral medication
4. Women either of non-childbearing potential or of childbearing potential willing to practice effective contraception for the duration of the study and for 6 months (Module 1, Module 4) and 24 months (Module 2) after the last dose of CT7001
5. Sexually active male patients must be willing to use condoms with all sexual partners for the duration of the study and for 3 months after the last dose of CT7001.
6. Provision of signed and dated, written informed consent

Core Exclusion Criteria:

1. Any other malignancy that has been active or treated within the past 3 years, with the exception of cervical intraepithelial neoplasia and non-melanoma skin cancer
2. Any unresolved toxicity (except alopecia) from prior therapy of ≥ CTCAE Grade 2
3. Spinal cord compression or brain metastases, unless asymptomatic, stable, and not requiring steroids for at least 4 weeks before the first dose of investigational product (IP)
4. Refractory nausea and vomiting, chronic gastrointestinal (GI) disease or previous significant bowel resection, with clinically significant sequelae that would preclude adequate absorption of CT7001
5. Uncontrolled seizures
6. Active infection requiring systemic antibiotic, antifungal, or antiviral medication
7. Severe or uncontrolled medical condition or psychiatric condition
8. Active bleeding diatheses
9. Renal transplant
10. Known hepatitis B, hepatitis C, or human immunodeficiency virus infection
11. Breastfeeding or pregnancy
12. Receipt of systemic cytotoxic treatment for the malignancy within 28 days or ≤ 5 half-lives, whichever is shorter before the first dose of IP
13. Receipt of non-cytotoxic treatment for the malignancy within 5 half-lives of the drug before the first dose of IP
14. Receipt of corticosteroids (at a dose \> 10 mg prednisone/day or equivalent) within 14 days before the first dose of IP
15. Receipt of any small-molecule investigational medicinal product (IMP) within 28 days or ≤ 5 half-lives, whichever is shorter before the first dose of IP
16. Receipt of any biological IMP (e.g., immune checkpoint blockers, antibodies, nanoparticles) within 42 days before the first dose of IP
17. Receipt of St John's Wort within 21 days before the first dose of IP or of another concomitant medication, herbal supplement, or food that is a strong inhibitor or inducer of CYP3A4, CYP2C19, CYP2D6, or P-glycoprotein (PGP) activity within 14 days before the first dose of CT7001
18. Receipt of a blood transfusion (blood or blood products) within 14 days before the first dose of IP
19. Known hypersensitivity to CT7001 or any excipient of the product
20. Impaired hepatic or renal function as demonstrated by any of the following laboratory values:

    1. Albumin \< 30 g/L
    2. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 2.5 × the upper limit of normal (ULN)
    3. \> 5.0 × ULN for patients with liver metastases
    4. Total bilirubin \> 1.5 × ULN
    5. Serum creatinine \> 1.5 × ULN
21. Liver function deteriorating in a manner that would likely make the participant meet the AST, ALT, or bilirubin levels specified above at the time of the first dose of IP
22. Other evidence of impaired hepatic synthesis function
23. Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:

    1. Absolute neutrophil count (ANC) \< 1.5 × 10\^9/L
    2. Platelet count \< 100 × 10\^9/L
    3. Haemoglobin \< 90 g/L
24. Persistent (\> 4 weeks) severe pancytopenia due to previous therapy rather than to disease (ANC \< 0.5 × 10\^9/L or platelets \< 50 x 10\^9/L)
25. Cardiac dysfunction (defined as myocardial infarction within 6 months of study entry, New York Heart Association Class II/III/IV heart failure, unstable angina, unstable cardiac arrhythmias, or left ventricular ejection fraction \< 55 percent)
26. Mean resting QT interval corrected for heart rate by the Fridericia formula (QTcF) \> 470 msec obtained from 3 electrocardiograms (ECGs) obtained within 5 minutes of each other prior to the first dose
27. Any clinically important abnormalities in rhythm, conduction, or morphology on resting ECG (e.g., complete left bundle branch block, third degree heart block). Controlled atrial fibrillation (AF) is permitted
28. Any factor that increases the risk of QTc prolongation or of arrhythmic events (e.g., heart failure, hypokalaemia, congenital long QT syndrome, immediate family history of long QT syndrome or unexplained sudden death under 40 years of age)
29. In the opinion of the Investigator, unlikely to comply with study procedures, restrictions, or requirements
30. A history of haemolytic anaemia or marrow aplasia
31. Has received a live-virus vaccination within 28 days or less of planned treatment start

Additional Module 1A Inclusion Criteria:

1. Histological, radiological or cytological confirmation of an advanced non-haematological malignancy not considered to be appropriate for further standard treatment
2. Module 1A biopsy cohort only : at least one tumour suitable for repeat biopsy

Additional Module 1A Exclusion Criteria:

1. International normalised ratio (INR) ≥1.5

Additional Module 1B Inclusion Criteria

1. Histological or cytological confirmation of metastasis or locally advanced tumour
2. At least one line of systemic anti-cancer therapy
3. Disease measurable by RECIST v1.1

Additional Module 1B-1 (TNBC Expansion) Inclusion Criteria:

1. Histologically-confirmed carcinoma of breast not expressing oestrogen receptor (ER) or progesterone receptor (PR) and negative for human epidermal growth factor receptor 2 (HER2)
2. Documented disease progression on or within 6 months of most recent cytotoxic prior cytotoxic chemotherapy
3. Disease measurable by RECIST v1.1
4. Must have received at least one cytotoxic chemotherapy for metastatic/locally advanced disease

Additional Module 1B-1 (TNBC Expansion) Exclusion Criteria:

1. No more than three lines of cytotoxic chemotherapy for metastatic/locally advanced disease
2. No advanced, symptomatic visceral metastases
3. No known symptomatic central nervous system (CNS) metastases, carcinomatous meningitis or leptomeningeal disease
4. Prior exposure to CT7001
5. Patients who are investigational site staff members directly involved in the conduct of the trial and their family members, site staff members otherwise supervised by the Investigator, or patients who are Carrick employees directly involved in the conduct of the trial

Additional Module 2 Inclusion Criteria:

1. Women only
2. Pre- or peri-menopausal women must have initiated LHRHa at least 28 days prior to first dose of CT7001/placebo
3. Histologically-confirmed, metastatic or locally advanced, ER+ve and/or PGR+ve and HER2-ve breast cancer
4. Part A only: Disease measurable by RECIST v1.1
5. Documented objective disease progression while on, or within 6 months after the end of, the most recent therapy
6. Must have received an aromatase inhibitor together with a CDK4/6 inhibitor in the same line of therapy for locally advanced or metastatic disease or for treatment of early breast cancer if the disease-free interval was \<12 months.
7. For Part B only: patients must have received at least 6 months clinical benefit with the CDK4/6 as a line of therapy immediately preceding study entry. Patients who received CDK4/6 inhibitor \< 6 months due to tolerability issues when at least 6 months aromatase inhibitor was received.
8. Ability to receive intramuscular injections.

Additional Module 2 Exclusion Criteria:

1. Prior therapy with fulvestrant
2. More than 2 lines of endocrine treatment for locally advanced or metastatic disease
3. Part A Only: Prior treatment with more than one line of cytotoxic chemotherapy for locally advanced or metastatic breast cancer.
4. Part B Only: Prior treatment with cytotoxic chemotherapy for locally advanced or metastatic breast cancer or treatment with a mammalian target of rapamycin (mTOR) inhibitor including, but not limited to, everolimus.
5. Patients with liver metastasis will be limited to approximately 30-40% of the enrolled patients. l
6. Known hypersensitivity to CT7001, fulvestrant or any excipient of the investigational products
7. Patients who are investigational site staff members directly involved in the conduct of the trial and their family members, site staff members otherwise supervised by the Investigator, or patients who are Carrick employees directly involved in the conduct of the trial

Additional Module 4 Inclusion Criteria:

1. Patients must be able to eat a high-fat meal, as provided by the study site, within a 30-minute period
2. Histological, radiological or cytological confirmation of an advanced non-haematological malignancy not considered to be appropriate for further standard treatment

Additional Module 4 Exclusion Criteria:

1. Patients who were unable to fast for at least 10 hours

Additional Module 6 Inclusion Criteria:

1. Histological, radiological or cytological confirmation of an advanced non- haematological malignancy not considered to be appropriate for further standard treatment.

Additional Module 6 Exclusion Criteria:

1. Any concurrent gastrointestinal conditions, not covered in Core Protocol Exclusion Criteria #4
2. Patients whom has received an agent that increases gastric pH (i.e. proton pump inhibitors (PPI), H2 antagonists) within 2 days or 5 half-lives, whichever is shorter, prior to PK Period Day 1.

Primary outcomes:
measure: Treatment-Emergent Adverse Events and Laboratory Abnormalities (Safety and Tolerability)
timeFrame: Screening to end of study
Secondary outcomes:
measure: Maximum Plasma Concentration of CT7001 (and Fulvestrant, where applicable) (Cmax)
timeFrame: After the first dose and during the dosing period
measure: Area Under the Curve (AUC)
timeFrame: After the first dose and during the dosing period
measure: Biological Activity Parameters (Biomarkers) in Peripheral Blood
timeFrame: Screening to end of treatment
measure: Anti-tumour Activity according to RECIST v1.1
timeFrame: Baseline until disease progression or withdrawal from the study
measure: Objective Response Rate (ORR)
timeFrame: Baseline until disease progression or withdrawal from the study
measure: Progression-Free Survival (PFS)
timeFrame: Baseline until disease progression or withdrawal from the study
Other outcomes:
Locations:
city: Tucson
country: United States
facility: Research Site 54
state: Arizona
city: Beverly Hills
country: United States
facility: Research Site 31
state: California
city: Tampa
country: United States
facility: Research Site 37
state: Florida
city: Chicago
country: United States
facility: Research Site 38
state: Illinois
city: Boston
country: United States
facility: Research Site 34
state: Massachusetts
city: Cincinnati
country: United States
facility: Research Site 47
state: Ohio
city: Columbus
country: United States
facility: Research Site 39
state: Ohio
city: Portland
country: United States
facility: Research Site 36
state: Oregon
city: Austin
country: United States
facility: Research Site 44
state: Texas
city: Dallas
country: United States
facility: Research Site 46
state: Texas
city: Salt Lake City
country: United States
facility: Research Site 48
state: Utah
city: Salem
country: United States
facility: Research Site 33
state: Virginia
city: Brighton
country: United Kingdom
facility: Research site 11
city: Cambridge
country: United Kingdom
facility: Research site 5
city: Glasgow
country: United Kingdom
facility: Research Site 7
city: Liverpool
country: United Kingdom
facility: Research Site 10
city: London
country: United Kingdom
facility: Research Site 9
city: London
country: United Kingdom
facility: Research Site 8
city: London
country: United Kingdom
facility: Research Site 3
city: Manchester
country: United Kingdom
facility: Research Site 1
city: Manchester
country: United Kingdom
facility: Research Site 4
city: Oxford
country: United Kingdom
facility: Research Site 2
city: Southampton
country: United Kingdom
facility: Research Site 6
Study officials:
affiliation: The Christie Hospital, Manchester, UK
name: Matthew Krebs, MBChB PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Sava GP, Fan H, Coombes RC, Buluwela L, Ali S. CDK7 inhibitors as anticancer drugs. Cancer Metastasis Rev. 2020 Sep;39(3):805-823. doi: 10.1007/s10555-020-09885-8.